U.S. Markets open in 7 hrs 45 mins

Twist Bioscience (TWST) Catches Eye: Stock Jumps 8%

Zacks Equity Research

Twist Bioscience Corporation TWST was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $21.74 –$33.20 in the past one-month time frame, witnessed a sharp increase yesterday.

The company's Zacks Consensus Estimate for the current quarter has moved higher over the past few weeks, suggesting that more solid trading could be ahead for Tailored Brands. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Twist Bioscience currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. 

Twist Bioscience Corporation Price

Twist Bioscience Corporation Price

Twist Bioscience Corporation price | Twist Bioscience Corporation Quote

Investors interested in the Medical – Biomedical and Genetics industry may consider Anika Therapeutics, Inc. ANIK, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is TWST going up? Or down? Predict to see what others think:Up or Down

Today's Best Stocks from Zacks
 
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
 
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
 
Twist Bioscience Corporation (TWST) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research